BUZZ-Citius rises as lymphoma drug shows benefit in patients before CAR-T therapy

Reuters03-04

** Shares of drugmaker Citius Oncology CTOR.O rise 1.89% to $1.08

** Co says early data shows its drug Lymphir may benefit patients with aggressive lymphoma, when administered before CAR-T therapy

**  High-risk diffuse large B-cell lymphoma is a fast‑growing blood cancer

** Co says 86% of 14 patients showed improvement after a single Lymphir dose administered before CAR-T, with over half reaching complete remission

**  Mild side effects were reported; all patients were able to proceed with CAR-T, co says

** Lymphir was approved in 2024 to treat certain adult patients with a group of rare blood cancers that affects the skin

** Shares down ~13% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2616849551?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-04 23:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616849551","market":"nz","top_or_hot":-1,"title":"BUZZ-Citius rises as lymphoma drug shows benefit in patients before CAR-T therapy","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Citius rises as lymphoma drug shows benefit in patients before CAR-T therapy</title></head><body><p>** Shares of drugmaker <a href=\"https://laohu8.com/S/CTOR\">Citius Oncology</a> <span>CTOR.O</span> rise 1.89% to $1.08 </p><p>** Co says early data shows its drug Lymphir may <span>benefit </span>patients with aggressive lymphoma, <span>when administered </span>before CAR-T therapy</p><p>**  High-risk diffuse large B-cell lymphoma is a fast‑growing blood cancer</p><p>** Co says 86% of 14 patients <span>showed improvemen</span>t after a single Lymphir dose <span>administered </span>before CAR-T, with over half reaching complete remission</p><p>**  Mild side effects <span>were </span>reported; all patients <span>were </span>able to proceed with CAR-T, co says</p><p>** Lymphir was approved in 2024 to treat certain adult patients with a group of rare blood cancers that affects the skin</p><p>** Shares down ~13% in 2025</p><p> (Reporting by Sahil Pandey in Bengaluru)</p><p> ((Sahil.Pandey@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Citius rises as lymphoma drug shows benefit in patients before CAR-T therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Citius rises as lymphoma drug shows benefit in patients before CAR-T therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-04 23:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Citius rises as lymphoma drug shows benefit in patients before CAR-T therapy</title></head><body><p>** Shares of drugmaker <a href=\"https://laohu8.com/S/CTOR\">Citius Oncology</a> <span>CTOR.O</span> rise 1.89% to $1.08 </p><p>** Co says early data shows its drug Lymphir may <span>benefit </span>patients with aggressive lymphoma, <span>when administered </span>before CAR-T therapy</p><p>**  High-risk diffuse large B-cell lymphoma is a fast‑growing blood cancer</p><p>** Co says 86% of 14 patients <span>showed improvemen</span>t after a single Lymphir dose <span>administered </span>before CAR-T, with over half reaching complete remission</p><p>**  Mild side effects <span>were </span>reported; all patients <span>were </span>able to proceed with CAR-T, co says</p><p>** Lymphir was approved in 2024 to treat certain adult patients with a group of rare blood cancers that affects the skin</p><p>** Shares down ~13% in 2025</p><p> (Reporting by Sahil Pandey in Bengaluru)</p><p> ((Sahil.Pandey@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CTOR","symbol_name":"CITIUS ONCOLOGY INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nL4N3ZS1F4:1","article_id":"2616849551","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616849551","pubTimestamp":1772636897,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Citius rises as lymphoma drug shows benefit in patients before CAR-T therapy** Shares of drugmaker Citius Oncology CTOR.O rise 1.89% to $1.08 ** Co says early data shows its drug Lymphir may benefit patients with aggressive lymphoma, when administered before CAR-T therapy** High-risk diffuse large B-cell lymphoma is a fastgrowing blood cancer** Co says 86% of 14 patients showed improvement after a single Lymphir dose administered before CAR-T, with over half reaching complete remission** Mild side effects were reported; all patients were able to proceed with CAR-T, co says** Lymphir was approved in 2024 to treat certain adult patients with a group of rare blood cancers that affects the skin** Shares down ~13% in 2025  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CTOR":"CITIUS ONCOLOGY INC","BK4007":"制药","BK4139":"生物科技","CTXR":"Citius Pharmaceuticals, Inc."},"translate_title":"淋巴瘤药物在CAR-T治疗前对患者有益，BUZZ-Citius上升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTXR":0.9,"CTOR":0.9},"content_text":"BUZZ-Citius rises as lymphoma drug shows benefit in patients before CAR-T therapy** Shares of drugmaker Citius Oncology CTOR.O rise 1.89% to $1.08 ** Co says early data shows its drug Lymphir may benefit patients with aggressive lymphoma, when administered before CAR-T therapy**  High-risk diffuse large B-cell lymphoma is a fast‑growing blood cancer** Co says 86% of 14 patients showed improvement after a single Lymphir dose administered before CAR-T, with over half reaching complete remission**  Mild side effects were reported; all patients were able to proceed with CAR-T, co says** Lymphir was approved in 2024 to treat certain adult patients with a group of rare blood cancers that affects the skin** Shares down ~13% in 2025 (Reporting by Sahil Pandey in Bengaluru) ((Sahil.Pandey@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2616849551","isCrawlerRequest":true}